Appropriateness of newborn screening for α1-antitrypsin deficiency

Jeffrey Teckman, Erin Pardee, R. Howell, David Mannino, Richard R. Sharp, Mark Brantly, Adam Wanner, Jamie Lamson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: The Alpha-1 Foundation convened a workshop to consider the appropriateness of newborn screening for α-1-antitrypsin (AAT) deficiency. METHODS: A review of natural history and technical data was conducted. RESULTS: Homozygous ZZ AAT deficiency is a common genetic disease occurring in 1 in 2000 to 3500 births; however, it is underrecognized and most patients are undiagnosed. AAT deficiency can cause chronic liver disease, cirrhosis, and liver failure in children and adults, and lung disease in adults. The clinical course is highly variable. Some neonates present with cholestatic hepatitis and some children require liver transplantation, but many patients remain well into adulthood. Some adults develop emphysema. There is no treatment for AAT liver disease, other than supportive care and liver transplant. There are no data on the effect of early diagnosis on liver disease. Avoidance of smoking is of proven benefit to reduce future lung disease, as is protein replacement therapy. Justifying newborn screening with the aim of reducing smoking and reducing adult lung disease-years in the future would be a significant paradigm shift for the screening field. Recent passage of the Genetic Information Nondiscrimination Act (GINA) and the Affordable Care Act may have a major effect on reducing the psychosocial and financial risks of newborn screening because many asymptomatic children would be identified. Data on the risk-benefit ratio of screening in the new legal climate are lacking. CONCLUSIONS: Workshop participants recommended a series of pilot studies focused on generating new data on the risks and benefits of newborn screening.

Original languageEnglish
Pages (from-to)199-203
Number of pages5
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume58
Issue number2
DOIs
StatePublished - Feb 1 2014

Fingerprint

Newborn Infant
Lung Diseases
Liver Diseases
Smoking
Patient Protection and Affordable Care Act
Education
Inborn Genetic Diseases
Emphysema
Liver Failure
Natural History
Climate
Liver Cirrhosis
Liver Transplantation
Hepatitis
Early Diagnosis
Chronic Disease
Odds Ratio
Parturition
Transplants
Liver

Keywords

  • genetic disease
  • hepatitis
  • liver disease
  • pediatrics
  • smoking

ASJC Scopus subject areas

  • Gastroenterology
  • Pediatrics, Perinatology, and Child Health

Cite this

Appropriateness of newborn screening for α1-antitrypsin deficiency. / Teckman, Jeffrey; Pardee, Erin; Howell, R.; Mannino, David; Sharp, Richard R.; Brantly, Mark; Wanner, Adam; Lamson, Jamie.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 58, No. 2, 01.02.2014, p. 199-203.

Research output: Contribution to journalArticle

Teckman, Jeffrey ; Pardee, Erin ; Howell, R. ; Mannino, David ; Sharp, Richard R. ; Brantly, Mark ; Wanner, Adam ; Lamson, Jamie. / Appropriateness of newborn screening for α1-antitrypsin deficiency. In: Journal of Pediatric Gastroenterology and Nutrition. 2014 ; Vol. 58, No. 2. pp. 199-203.
@article{46394c80af784b22beba32ff85fd7002,
title = "Appropriateness of newborn screening for α1-antitrypsin deficiency",
abstract = "OBJECTIVE: The Alpha-1 Foundation convened a workshop to consider the appropriateness of newborn screening for α-1-antitrypsin (AAT) deficiency. METHODS: A review of natural history and technical data was conducted. RESULTS: Homozygous ZZ AAT deficiency is a common genetic disease occurring in 1 in 2000 to 3500 births; however, it is underrecognized and most patients are undiagnosed. AAT deficiency can cause chronic liver disease, cirrhosis, and liver failure in children and adults, and lung disease in adults. The clinical course is highly variable. Some neonates present with cholestatic hepatitis and some children require liver transplantation, but many patients remain well into adulthood. Some adults develop emphysema. There is no treatment for AAT liver disease, other than supportive care and liver transplant. There are no data on the effect of early diagnosis on liver disease. Avoidance of smoking is of proven benefit to reduce future lung disease, as is protein replacement therapy. Justifying newborn screening with the aim of reducing smoking and reducing adult lung disease-years in the future would be a significant paradigm shift for the screening field. Recent passage of the Genetic Information Nondiscrimination Act (GINA) and the Affordable Care Act may have a major effect on reducing the psychosocial and financial risks of newborn screening because many asymptomatic children would be identified. Data on the risk-benefit ratio of screening in the new legal climate are lacking. CONCLUSIONS: Workshop participants recommended a series of pilot studies focused on generating new data on the risks and benefits of newborn screening.",
keywords = "genetic disease, hepatitis, liver disease, pediatrics, smoking",
author = "Jeffrey Teckman and Erin Pardee and R. Howell and David Mannino and Sharp, {Richard R.} and Mark Brantly and Adam Wanner and Jamie Lamson",
year = "2014",
month = "2",
day = "1",
doi = "10.1097/MPG.0000000000000196",
language = "English",
volume = "58",
pages = "199--203",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Appropriateness of newborn screening for α1-antitrypsin deficiency

AU - Teckman, Jeffrey

AU - Pardee, Erin

AU - Howell, R.

AU - Mannino, David

AU - Sharp, Richard R.

AU - Brantly, Mark

AU - Wanner, Adam

AU - Lamson, Jamie

PY - 2014/2/1

Y1 - 2014/2/1

N2 - OBJECTIVE: The Alpha-1 Foundation convened a workshop to consider the appropriateness of newborn screening for α-1-antitrypsin (AAT) deficiency. METHODS: A review of natural history and technical data was conducted. RESULTS: Homozygous ZZ AAT deficiency is a common genetic disease occurring in 1 in 2000 to 3500 births; however, it is underrecognized and most patients are undiagnosed. AAT deficiency can cause chronic liver disease, cirrhosis, and liver failure in children and adults, and lung disease in adults. The clinical course is highly variable. Some neonates present with cholestatic hepatitis and some children require liver transplantation, but many patients remain well into adulthood. Some adults develop emphysema. There is no treatment for AAT liver disease, other than supportive care and liver transplant. There are no data on the effect of early diagnosis on liver disease. Avoidance of smoking is of proven benefit to reduce future lung disease, as is protein replacement therapy. Justifying newborn screening with the aim of reducing smoking and reducing adult lung disease-years in the future would be a significant paradigm shift for the screening field. Recent passage of the Genetic Information Nondiscrimination Act (GINA) and the Affordable Care Act may have a major effect on reducing the psychosocial and financial risks of newborn screening because many asymptomatic children would be identified. Data on the risk-benefit ratio of screening in the new legal climate are lacking. CONCLUSIONS: Workshop participants recommended a series of pilot studies focused on generating new data on the risks and benefits of newborn screening.

AB - OBJECTIVE: The Alpha-1 Foundation convened a workshop to consider the appropriateness of newborn screening for α-1-antitrypsin (AAT) deficiency. METHODS: A review of natural history and technical data was conducted. RESULTS: Homozygous ZZ AAT deficiency is a common genetic disease occurring in 1 in 2000 to 3500 births; however, it is underrecognized and most patients are undiagnosed. AAT deficiency can cause chronic liver disease, cirrhosis, and liver failure in children and adults, and lung disease in adults. The clinical course is highly variable. Some neonates present with cholestatic hepatitis and some children require liver transplantation, but many patients remain well into adulthood. Some adults develop emphysema. There is no treatment for AAT liver disease, other than supportive care and liver transplant. There are no data on the effect of early diagnosis on liver disease. Avoidance of smoking is of proven benefit to reduce future lung disease, as is protein replacement therapy. Justifying newborn screening with the aim of reducing smoking and reducing adult lung disease-years in the future would be a significant paradigm shift for the screening field. Recent passage of the Genetic Information Nondiscrimination Act (GINA) and the Affordable Care Act may have a major effect on reducing the psychosocial and financial risks of newborn screening because many asymptomatic children would be identified. Data on the risk-benefit ratio of screening in the new legal climate are lacking. CONCLUSIONS: Workshop participants recommended a series of pilot studies focused on generating new data on the risks and benefits of newborn screening.

KW - genetic disease

KW - hepatitis

KW - liver disease

KW - pediatrics

KW - smoking

UR - http://www.scopus.com/inward/record.url?scp=84894102382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894102382&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000000196

DO - 10.1097/MPG.0000000000000196

M3 - Article

C2 - 24121147

AN - SCOPUS:84894102382

VL - 58

SP - 199

EP - 203

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 2

ER -